Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Pharming Group N.V (PHAR) Equity Ratio: 2019-2025

Historic Equity Ratio for Pharming Group N.V (PHAR) over the last 5 years, with Sep 2025 value amounting to 0.56.

  • Pharming Group N.V's Equity Ratio rose 5.27% to 0.56 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.56, marking a year-over-year increase of 5.27%. This contributed to the annual value of 0.55 for FY2024, which is 16.92% up from last year.
  • Per Pharming Group N.V's latest filing, its Equity Ratio stood at 0.56 for Q3 2025, which was up 4.06% from 0.54 recorded in Q2 2025.
  • Pharming Group N.V's Equity Ratio's 5-year high stood at 0.56 during Q3 2025, with a 5-year trough of 0.46 in Q1 2021.
  • Over the past 3 years, Pharming Group N.V's median Equity Ratio value was 0.53 (recorded in 2024), while the average stood at 0.51.
  • In the last 5 years, Pharming Group N.V's Equity Ratio fell by 8.17% in 2023 and then grew by 16.92% in 2024.
  • Pharming Group N.V's Equity Ratio (Quarterly) stood at 0.49 in 2021, then dropped by 1.02% to 0.48 in 2022, then fell by 1.65% to 0.47 in 2023, then climbed by 16.92% to 0.55 in 2024, then increased by 5.27% to 0.56 in 2025.
  • Its Equity Ratio was 0.56 in Q3 2025, compared to 0.54 in Q2 2025 and 0.53 in Q1 2025.